非アルコール性脂肪性肝炎治療の世界市場レポート 2025年

非アルコール性脂肪性肝炎治療の市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR40.0％で138億3,000万米ドルに成長します。予測期間の成長は、医薬品開発の進歩、疾患に対する意識の高まり、有病率とリスク要因の上昇、個別化医療へのシフトに起因すると考えられます。予測期間の主な動向には、患者中心のアプローチ、技術の進歩、標的治療、規制状況、研究の進歩などがあります。

インスリン抵抗性の有病率の上昇は、非アルコール性脂肪肝炎（NASH）治療市場の成長に大きく寄与しています。インスリン抵抗性は、筋肉、脂肪、肝細胞がインスリンに十分に反応できず、血流からグルコースを吸収することが困難になり、血糖値の上昇につながる場合に起こります。この状態は、不健康な生活習慣、糖分の過剰摂取、遺伝的要因などと関連することが多くあります。糖尿病やNASH治療を必要とする他の肝臓関連疾患の割合が増加しているため、インスリン抵抗性への注目は強まっています。例えば、2022年1月、ベルギーを拠点とする世界の糖尿病団体である国際糖尿病連合（International Diabetes Federation）の報告によると、糖尿病は現在20歳から79歳の5億3,700万人が罹患しており、これは10人に1人の割合に相当します。この数字は、2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。さらに、2024年1月、米国を拠点とするがん擁護に重点を置く非営利団体である米国がん協会は、肝臓がんの新規患者数が2023年の4万1,210人から2024年には4万1,630人に増加すると予測しました。このように、様々な肝臓疾患や糖尿病関連疾患によるインスリン抵抗性の有病率の増加が、NASH治療に対する需要を牽引することになります。

肥満率の上昇は、非アルコール性脂肪性肝炎治療市場の急成長に大きく寄与しています。過剰な体脂肪蓄積を特徴とする肥満は、NASHの発症率上昇を含む様々な健康合併症と関連しています。世界保健機関（WHO）は、2022年3月に全世界で10億人以上が肥満の影響を受けていると報告しています。この数字はさらに増加し、2025年には1億6,700万人に達すると予想されています。この肥満症例の急増は、NASHの有病率の増加と直接相関しています。この関連性が非アルコール性脂肪性肝炎治療に対する世界の需要の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の非アルコール性脂肪性肝炎治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の非アルコール性脂肪性肝炎治療市場：成長率分析
• 世界の非アルコール性脂肪性肝炎治療市場の実績：規模と成長、2019～2024年
• 世界の非アルコール性脂肪性肝炎治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の非アルコール性脂肪性肝炎治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非アルコール性脂肪性肝炎治療市場：薬の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• ビタミンE・ピオグリタゾン
• オカリバ
• エラフィブラノール
• セロンセルチブ・セニクリビロック
• オベチコール酸
• その他
• 世界の非アルコール性脂肪性肝炎治療市場：テストの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 血液検査
• 肝生検
• 画像診断
• 世界の非アルコール性脂肪性肝炎治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売および専門薬局
• その他
• 世界の非アルコール性脂肪性肝炎治療市場：ビタミンE・ピオグリタゾンのサブセグメンテーション、実績と予測、2019～2024年、2024～2029年、2034年
• ビタミンEサプリメント
• ピオグリタゾンベース製剤
• 世界の非アルコール性脂肪性肝炎治療市場：オカリバのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• NASH用オカリバ（オベチコール酸）
• 世界の非アルコール性脂肪性肝炎治療市場：エラフィブラノールのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エラフィブラノールベース治療
• 世界の非アルコール性脂肪性肝炎治療市場：セロンセルチブ・セニクリビロックのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• セロンセルチブ製剤
• セニクリビロック製剤
• 世界の非アルコール性脂肪性肝炎治療市場：オベチコール酸のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オベチコール酸のその他の製剤
• 世界の非アルコール性脂肪性肝炎治療市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 臨床試験における新規薬剤
• 併用療法

第7章 地域別・国別分析

• 世界の非アルコール性脂肪性肝炎治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の非アルコール性脂肪性肝炎治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非アルコール性脂肪性肝炎治療市場：競合情勢
• 非アルコール性脂肪性肝炎治療市場：企業プロファイル
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Galmed Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Genfit S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Zydus Cadila Healthcare Limited Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Novo Nordisk A/S
• Immuron Ltd.
• Inventiva Pharma SA
• NGM Biopharmaceuticals Inc.
• Galectin Therapeutics Inc.
• Madrigal Pharmaceuticals Corporation
• Intercept Pharmaceuticals Inc.
• Cirius Therapeutics Inc.
• Viking Therapeutics Inc.
• Eli Lilly and Company
• Terns Pharmaceuticals Inc.
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非アルコール性脂肪性肝炎治療市場2029年：新たな機会を提供する国
• 非アルコール性脂肪性肝炎治療市場2029年：新たな機会を提供するセグメント
• 非アルコール性脂肪性肝炎治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-alcoholic steatohepatitis treatment involves lifestyle modifications such as adhering to a healthy diet, regulating blood sugar levels, and achieving weight loss to address liver disease. This form of treatment targets individuals who consume minimal or no alcohol but develop fatty liver conditions. Such conditions trigger liver cell damage and inflammation, which may progress to cirrhosis.

The primary drugs used in non-alcoholic steatohepatitis treatment include vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, obeticholic acid, among others. Vitamin E and pioglitazone play pivotal roles in treating this condition. Vitamin E, a crucial fat-soluble nutrient vital for immune health, works to ameliorate NASH by reducing oxidative stress on hepatocytes, thereby mitigating liver injury and inflammation. Conversely, pioglitazone aids in enhancing insulin sensitivity and managing elevated blood sugar levels associated with type 2 diabetes. Diagnosis and assessment of treatment typically involve blood tests, liver biopsy, and imaging procedures conducted in hospital pharmacies, retail outlets, specialty pharmacies, and other medical facilities.

The non-alcoholic steatohepatitis treatment market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis treatment market statistics, including non-alcoholic steatohepatitis treatment industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis treatment market share, detailed non-alcoholic steatohepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. This non-alcoholic steatohepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $2.6 billion in 2024 to $3.6 billion in 2025 at a compound annual growth rate (CAGR) of 38.5%. The growth in the historic period can be attributed to rising prevalence of NASH, growing awareness and diagnosis, lifestyle changes and obesity epidemic, clinical research, healthcare infrastructure and access, regulatory support and clinical trials.

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $13.83 billion in 2029 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to advancements in drug development, increased disease awareness, rising prevalence and risk factor, shift towards personalized medicine. Major trends in the forecast period include patient-centric approach, technological advancements, targeted therapies, regulatory landscape, advancements in research.

The rising prevalence of insulin resistance has significantly contributed to the growth of the non-alcoholic steatohepatitis (NASH) treatment market. Insulin resistance occurs when muscle, fat, and liver cells fail to respond adequately to insulin, making it difficult for them to absorb glucose from the bloodstream, which leads to elevated blood sugar levels. This condition is often linked to an unhealthy lifestyle, excessive sugar intake, and genetic factors. The focus on insulin resistance has intensified due to the increasing rates of diabetes and other liver-related conditions that require NASH treatment. For instance, in January 2022, a report from the International Diabetes Federation, a Belgium-based global diabetes organization, indicated that diabetes currently affects 537 million people aged 20 to 79, representing one in every ten individuals. This number is projected to rise to 643 million by 2030 and 783 million by 2045. Additionally, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization focused on cancer advocacy, forecasted that the number of new liver cancer cases would increase to 41,630 in 2024, up from 41,210 in 2023. Consequently, the growing prevalence of insulin resistance due to various liver and diabetes-related diseases will drive demand for NASH treatment.

The escalating obesity rates significantly contribute to the burgeoning growth of the non-alcoholic steatohepatitis treatment market. Obesity, characterized by excessive body fat accumulation, is associated with various health complications, including the rising incidence of NASH. The World Health Organization reported over 1 billion individuals affected by obesity globally in March 2022. This figure is expected to rise, impacting 167 million people by 2025. This surge in obesity cases directly correlates with an increased prevalence of NASH. This connection drives the demand for non-alcoholic steatohepatitis treatments worldwide.

A prominent trend in the non-alcoholic steatohepatitis treatment market is the development of innovative drugs tailored to mitigate drug side effects. Pfizer Inc., in May 2022, secured FDA fast-track designation for their investigational combination therapy targeting NASH with liver fibrosis. Ervogastat (a DGAT2 inhibitor) and Clesacostat (an ACCi) have shown promise as potential NASH drugs. This FDA-backed initiative by Pfizer underscores the industry's inclination towards developing drugs addressing NASH and its associated complications.

In the realm of non-alcoholic steatohepatitis treatment, leading companies are pioneering innovative solutions like endogenous hormones to expand their market reach, drive sales, and bolster revenue. A noteworthy example is 89bio Inc's milestone achievement in September 2023, securing the U.S. FDA's Breakthrough Therapy Designation (BTD) for Pegozafermin, targeting individuals grappling with nonalcoholic steatohepatitis (NASH). Pegozafermin, an engineered glycoPEGylated analog of fibroblast growth factor 21, represents a unique approach in NASH and severe hypertriglyceridemia (SHTG) treatment. Its distinctive formulation integrates specialized glycoPEGylation technology, enabling an extended half-life without compromising potency. This innovative design significantly enhances the product's efficacy in modulating critical factors associated with lipid metabolism, NASH, and hypertriglyceridemia, exhibiting promise in reducing triglycerides, managing glycemic levels, mitigating steatosis, inflammation, and fibrosis.

In July 2022, Advanz Pharma, a pharmaceutical company headquartered in the UK, completed the acquisition of Intercept Pharmaceuticals for an undisclosed sum. This acquisition encompasses the rights outside the United States for the commercialization of Ocaliva(R) (obeticholic acid), an orphan drug utilized in treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals, Inc., based in the United States, specializes in the development of innovative synthetic bile acid analogs targeting chronic liver diseases and non-alcoholic steatohepatitis.

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Vitamin E And Pioglitazone; Ocaliva; Elafibranor; Selonsertib And cenicriviroc; Obeticholic Acid; Other Drugs Types
• 2) By Test Type: Blood Tests; Liver Biopsy; Imaging Procedures
• 3) By End User: Hospital Pharmacies; Retail And Specialty Pharmacies; Other End Users
• Subsegments:
• 1) By Vitamin E And Pioglitazone: Vitamin E Supplements; Pioglitazone-Based Formulations.
• 2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
• 3) By Elafibranor: Elafibranor-Based Treatments
• 4) By Selonsertib And Cenicriviroc: Selonsertib Formulations; Cenicriviroc Formulations
• 5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
• 6) By Other Drug Types: Novel Agents In Clinical Trials; Combination Therapies
• Companies Mentioned: AstraZeneca PLC; Galmed Pharmaceuticals Ltd.; Genfit S.A.; Zydus Cadila Healthcare Limited; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics

3. Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Alcoholic Steatohepatitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Alcoholic Steatohepatitis Treatment Market Growth Rate Analysis
• 5.4. Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Alcoholic Steatohepatitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Alcoholic Steatohepatitis Treatment Total Addressable Market (TAM)

6. Non-Alcoholic Steatohepatitis Treatment Market Segmentation

• 6.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin E And Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib And cenicriviroc
• Obeticholic Acid
• Other Drugs Types
• 6.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Liver Biopsy
• Imaging Procedures
• 6.3. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail And Specialty Pharmacies
• Other End Users
• 6.4. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Vitamin E And Pioglitazone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin E Supplements
• Pioglitazone-Based Formulations
• 6.5. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Ocaliva, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ocaliva (Obeticholic Acid) For NASH
• 6.6. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Elafibranor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Elafibranor-Based Treatments
• 6.7. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Selonsertib And Cenicriviroc, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selonsertib Formulations
• Cenicriviroc Formulations
• 6.8. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Other Formulations Of Obeticholic Acid
• 6.9. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Novel Agents In Clinical Trials
• Combination Therapies

7. Non-Alcoholic Steatohepatitis Treatment Market Regional And Country Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market

• 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Alcoholic Steatohepatitis Treatment Market

• 9.1. China Non-Alcoholic Steatohepatitis Treatment Market Overview
• 9.2. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Alcoholic Steatohepatitis Treatment Market

• 10.1. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Treatment Market

• 11.1. Japan Non-Alcoholic Steatohepatitis Treatment Market Overview
• 11.2. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Treatment Market

• 12.1. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Treatment Market

• 13.1. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Treatment Market

• 14.1. South Korea Non-Alcoholic Steatohepatitis Treatment Market Overview
• 14.2. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Treatment Market

• 15.1. Western Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• 15.2. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Treatment Market

• 16.1. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Treatment Market

• 17.1. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Alcoholic Steatohepatitis Treatment Market

• 18.1. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis Treatment Market

• 19.1. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis Treatment Market

• 20.1. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market

• 21.1. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• 21.2. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis Treatment Market

• 22.1. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Alcoholic Steatohepatitis Treatment Market

• 23.1. North America Non-Alcoholic Steatohepatitis Treatment Market Overview
• 23.2. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Alcoholic Steatohepatitis Treatment Market

• 24.1. USA Non-Alcoholic Steatohepatitis Treatment Market Overview
• 24.2. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis Treatment Market

• 25.1. Canada Non-Alcoholic Steatohepatitis Treatment Market Overview
• 25.2. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Alcoholic Steatohepatitis Treatment Market

• 26.1. South America Non-Alcoholic Steatohepatitis Treatment Market Overview
• 26.2. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis Treatment Market

• 27.1. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis Treatment Market

• 28.1. Middle East Non-Alcoholic Steatohepatitis Treatment Market Overview
• 28.2. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis Treatment Market

• 29.1. Africa Non-Alcoholic Steatohepatitis Treatment Market Overview
• 29.2. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape
• 30.2. Non-Alcoholic Steatohepatitis Treatment Market Company Profiles
  • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Galmed Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Genfit S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Zydus Cadila Healthcare Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Non-Alcoholic Steatohepatitis Treatment Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Novo Nordisk A/S
• 31.3. Immuron Ltd.
• 31.4. Inventiva Pharma SA
• 31.5. NGM Biopharmaceuticals Inc.
• 31.6. Galectin Therapeutics Inc.
• 31.7. Madrigal Pharmaceuticals Corporation
• 31.8. Intercept Pharmaceuticals Inc.
• 31.9. Cirius Therapeutics Inc.
• 31.10. Viking Therapeutics Inc.
• 31.11. Eli Lilly and Company
• 31.12. Terns Pharmaceuticals Inc.
• 31.13. Pfizer Inc.
• 31.14. Merck & Co. Inc.
• 31.15. AbbVie Inc.

32. Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis Treatment Market

35. Non-Alcoholic Steatohepatitis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Non-Alcoholic Steatohepatitis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Alcoholic Steatohepatitis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Alcoholic Steatohepatitis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer